Big Pharma Must Diversify To Tackle Antimicrobial Resistance
Biotechs Lead On R&D But Need Resources
Executive Summary
Big pharma must bet on biotech if the industry is to tackle the looming issue of superbugs, argues the Access To Medicine Foundation.